Evidence map›Paper›PMID 29535160›Full record

ArticleMolecular & cellular proteomics : MCP2018

Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.

Mohamed Ali Maroui, Ghizlane Maarifi, Francis P McManus, Frédéric Lamoliatte, Pierre Thibault, Mounira K Chelbi-Alix

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. SUMOylation and Viral Infections of the Brain.Pathogens (Basel, Switzerland) · 2022
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. SUMO and Cytoplasmic RNA Viruses: From Enemies to Best Friends.Advances in experimental medicine and biology · 2020
    Review
  13. Review
  14. [Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mohamed Ali MarouiFrom the ‡INSERM UMR-S1124, 75006 Paris, France.
Ghizlane MaarifiFrom the ‡INSERM UMR-S1124, 75006 Paris, France.
Francis P McManus¶Institute for Research in Immunology and Cancer, H3T 1J4, Québec, Canada.
Frédéric Lamoliatte¶Institute for Research in Immunology and Cancer, H3T 1J4, Québec, Canada.
Pierre Thibault¶Institute for Research in Immunology and Cancer, H3T 1J4, Québec, Canada; pierre.thibault@umontreal.ca mounira.chelbi-alix@parisdescartes.fr.ORCID 0000-0001-5993-0331
Mounira K Chelbi-AlixFrom the ‡INSERM UMR-S1124, 75006 Paris, France; pierre.thibault@umontreal.ca mounira.chelbi-alix@parisdescartes.fr.
Délégation Paris 5 · FRInstitute for Research in Immunology and Cancer · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report that interferon (IFN) α treatment at short and long periods increases the global cellular SUMOylation and requires the presence of the SUMO E3 ligase promyelocytic leukemia protein (PML), the organizer of PML nuclear bodies (NBs). Several PML isoforms (PMLI-PMLVII) derived from a single

Indexed as

HEK293 CellsHumansInterferon-alphaPromyelocytic Leukemia ProteinSumoylationInterferon-alphaPromyelocytic Leukemia ProteinCytokines*InterferonMass SpectrometryPMLPost-translational modifications*SUMOSystems biology*Tandem Mass SpectrometryUBC9Ubiquitinases

Identifiers

PMID29535160
PMCPMC5986244
OpenAlexW2789961905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.